Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007584
Filing Date
2025-05-13
Accepted
2025-05-13 16:36:35
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20250331x10q.htm   iXBRL 10-Q 867279
2 EX-31.1 anvs-20250331xex31d1.htm EX-31.1 12670
3 EX-31.2 anvs-20250331xex31d2.htm EX-31.2 12724
4 EX-32.1 anvs-20250331xex32d1.htm EX-32.1 7907
  Complete submission text file 0001558370-25-007584.txt   4841531

Data Files

Seq Description Document Type Size
5 EX-101.SCH anvs-20250331.xsd EX-101.SCH 40617
6 EX-101.CAL anvs-20250331_cal.xml EX-101.CAL 31083
7 EX-101.DEF anvs-20250331_def.xml EX-101.DEF 136250
8 EX-101.LAB anvs-20250331_lab.xml EX-101.LAB 320733
9 EX-101.PRE anvs-20250331_pre.xml EX-101.PRE 243364
67 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20250331x10q_htm.xml XML 767266
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 25940796
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)